European Alzheimer’s Alliance Vice-Chair, Christophe Hansen MEP (EPP, Luxembourg), has submitted a written question to the European Commission asking about the place of dementia and cognitive disabilities in the future research priorities of the EU, including within Horizon Europe. The question submitted was as follows:
"Dementia affects almost 8 million people in the European Union and the number is expected to double by 2050. Currently, there is no cure for dementia, there is no disease-modifying treatment and only four symptom-modifying drugs exist on the market. As such, research into new ways of detecting, treating and supporting people with dementia is vitally important:
-
How much money has been allocated to dementia and Alzheimer’s research projects as part of Horizon 2020 and does this result in an increase, decrease or plateau in the funding for dementia and Alzheimer’s research in the forthcoming Horizon Europe research programme?
-
Will research into dementia and Alzheimer’s disease be identified as a specific priority as part of the Horizon Europe research programme?
-
Does the Commission consider to prioritize dementia as a future “mission”, as was done for cancer?"